人参和多边形多花配方在阿尔茨海默病中保护大脑功能
Jing-Jing Liu1, Feng Wei1, Ya-Dan Wang1
1National Institutes for Food and Drug Control, Beijing, China.
Frontiers in pharmacology
|March 7, 2025
概括
这项研究表明,Panax人参和Polygonum多花配方 (GSPM) 改善了阿尔茨海默氏症患者的认知功能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,目前没有有效的治疗方法.
- 草药配方GSPM (Panax ginseng和Polygonum multiflorum) 显示出潜在的神经保护作用,但其在阿尔茨海默病中的机制需要研究.
研究的目的:
- 在阿尔茨海默氏症小鼠模型中研究GSPM的治疗疗效和机制.
- 评估GSPM对认知功能,神经炎症,氧化应激,衰老和肠道微生物群的影响.
主要方法:
- 衰老加速小鼠易受8 (SAMP8) 的小鼠被用GSPM或donepezil治疗.
- 评估了认知功能,海马体形态,神经元亡,微质,星质和分子标记物.
- 在体外分析了肠道微生物群组成和神经元反应,包括AMPK/Sirt1通路.
主要成果:
- 在AD小鼠中,GSPM改善了认知功能,减少了海马的损伤,并减少了神经元亡.
- GSPM缓解了神经炎症,氧化应激和衰老,并调节了肠道微生物群的组成.
- 在体外,GSPM保护神经元免受Aβ1-42毒性,降低了细胞亡,并激活了AMPK/Sirt1通路.
结论:
- GSPM显示出对抗阿尔茨海默病的显著保护作用.
- 这些效应通过抑制炎症,氧化和衰老来调节,可能通过Sirt1信号传递.
- GSPM代表了针对阿尔茨海默病的新型治疗方法.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35